Whitepapers

Have you written a paper on a specific application method, or perhaps researched a peculiar condition? Share with your fellow veterinarians and submit your own papers here!

Evaluation of the distribution of enrofloxacin by circulating leukocytes to sites of inflammation in dogs

.pdf file (613.52 KB)

WBCs were responsible for the transport and release of 14C-ENR at sites of inflammation. Accumulation of drug by WBCs might increase the concentration of drug at the site of infection, thus facilitating therapeutic success.

Boothe et al

March 12, 2010

Tags dog inflamed tissues

Category Application method

Technical Update - J Blondeau

.pdf file (258.34 KB)

Optimising antimicrobial therapy – the MPC as a strategy to minimise antibiotic resistance

Bayer AG

March 12, 2010

Tags Mutant Prevention Concentration

Category Pest

New concepts in antimicrobial susceptibility testing

.pdf file (520.37 KB)

Current measurements of antimicrobial susceptibility or resistance utilize a standardized bacterial inoculum (105 cfu ⁄ mL) exposed to varying drug concentrations in a test tube. Following incubation under ideal conditions, the lowest drug concentration inhibiting growth is the minimum inhibitory concentration (MIC).

Joseph M. Blondeau

March 12, 2010

Tags Veterinary Dermatology 2009

Category Pest

Efficacy of enrofloxacin and marbofloxacin against bacterial isolates from dogs and cats - in vitro resistance study

.pdf file (2.90 MB)

In 2009, Muller et al published the results of a large study that examined the susceptibility of bacterial isolates from dogs and cats to the fluoroquinolone antimicrobials Enrofloxacin (Baytril) and Marbofloxacin.

Elisabeth Müller

March 10, 2010

Category Condition

Technical Update - Baytril

.pdf file (919.13 KB)

In 2009, Muller et al published the results of a large study that examined the susceptibility of bacterial isolates from dogs and cats to the fluoroquinolone antimicrobials Enrofloxacin (Baytril) and Marbofloxacin. This Technical Update examines the study, the results and the implications for the use of these important therapeutic agents in clinical practice.

Bayer AG

March 12, 2010

Tags Muller dog cat study

Category Condition